Alemtuzumab FDA Link

An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.

Also Known As:

Campath; Campath 1H; Campath 1G; Campath 1M; Campath-1-G; Campath-1G; Campath-1H; Campath-1M; Lemtrada; MabCambath; Monoclonal Antibody Campath-1H; Antibody Campath-1H, Monoclonal; Campath 1 G; Campath-1H, Monoclonal Antibody; Campath1G; Campath1H; Monoclonal Antibody Campath 1H

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Alemtuzumab: 1758
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Alemtuzumab: 1758
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Alemtuzumab: 1758

Gery Courouble Selected Research

Gery Courouble Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure